Option chain shows key data for Intensity Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Intensity Therapeutics.

Intensity Therapeutics (NASDAQ:INTS) Stock, Option Chain

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Wall Street

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ALMS

BRZE

ELVN

INTS

TERN

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Penny Stocks

Small Cap

Intraday Update

Movers

ADBE

ADTX

ALEC

APLS

ASLE

ASYS

ATUS

BLND

CDXS

CPHC

CPTN

ENPH

ESPR

FRGT

HRYU

MIND

MRNA

MYND

NOVA

NXTC

NXTP

OCUL

OPEN

PACB

PLUG

RDFN

RILY

RPHM

SVMH

TPIC

VCIG

VIEW

Shares of Amtech Systems, Inc.  (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

AUVI

EKSO

NUBI

PHIO

SNOA

STTK

Shares of  Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.

Nxu, shares rose 42.1% to $0.0278 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Earnings

Press Releases

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Alliance Global Partners

HC Wainwright & Co.

Benchmark

Comments

Intensity Therapeutics

Intensity Therapeutics (INTS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga